Guggenheim has downgraded Exact Sciences Corp (EXAS) to Neutral from Buy, effective November 20, 2025. The stock is currently priced at $101.00.
This downgrade suggests increased caution regarding Exact Sciences' outlook, possibly reflecting concerns about competitive pressures and execution risks.
Exact Sciences is a biotechnology firm based in Madison, Wisconsin, focusing on cancer screening and diagnostics. The company employs 6,900 people and has a market cap of $12.7 billion. Its flagship product, the Cologuard test, is a non-invasive screening tool for colorectal cancer.
The firm is set to report earnings on August 4, 2026, with an estimated EPS of $0.09 and revenue of $935.5 million. Recent performance has shown mixed results, with Q3 2025 reporting an EPS of -$0.10, missing estimates by 40.1%.
Analyst consensus remains a Buy, with 12 Strong Buy, 14 Buy, and 4 Hold ratings as of November 1, 2025. However, recent actions from various firms, including William Blair and Wells Fargo, have also indicated downgrades, highlighting shifting sentiments in the market.